(Q38105253)

28 August 2017

title

Important and critical scientific aspects in pharmacogenomics analysis: lessons from controversial results of tamoxifen and CYP2D6 studies (English)

1 reference

28 August 2017

1 reference

1 reference

Kazuma Kiyotani

1

1 reference

28 August 2017

Taisei Mushiroda

series ordinal

2

1 reference

28 August 2017

Hitoshi Zembutsu

series ordinal

3

1 reference

28 August 2017

Yusuke Nakamura

series ordinal

4

1 reference

28 August 2017

publication date

9 May 2013

1 reference

Journal of Human Genetics

28 August 2017

published in

1 reference

28 August 2017

volume

58

1 reference

28 August 2017

issue

6

1 reference

28 August 2017

page(s)

327-333

1 reference

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

Identification of human CYP forms involved in the activation of tamoxifen and irreversible binding to DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

Large interindividual variability in the in vitro formation of tamoxifen metabolites related to the development of genotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

Reverse geometrical selectivity in glucuronidation and sulfation of cis- and trans-4-hydroxytamoxifens by human liver UDP-glucuronosyltransferases and sulfotransferases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

Quaternary ammonium-linked glucuronidation of trans-4-hydroxytamoxifen, an active metabolite of tamoxifen, by human liver microsomes and UDP-glucuronosyltransferase 1A4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

Glucuronidation of active tamoxifen metabolites by the human UDP glucuronosyltransferases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

Quaternary ammonium-linked glucuronidation of tamoxifen by human liver microsomes and UDP-glucuronosyltransferase 1A4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

Characterization of tamoxifen and 4-hydroxytamoxifen glucuronidation by human UGT1A4 variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

Impaired tamoxifen metabolism reduces survival in familial breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

Association between genetic polymorphisms of CYP2D6 and outcomes in breast cancer patients with tamoxifen treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

The risk of recurrence in breast cancer patients treated with tamoxifen: polymorphisms of CYP2D6 and ABCB1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

Genetic polymorphisms of CYP2D6 10 and CYP2C19 2, 3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial and Re: CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patien

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: expanded polymorphism coverage improves risk stratification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

Lessons for pharmacogenomics studies: association study between CYP2D6 genotype and tamoxifen response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

Pharmacogenomics of tamoxifen: roles of drug metabolizing enzymes and transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

CYP2C19*2 polymorphism is associated with increased survival in breast cancer patients using tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

SULT1A1, CYP2C19 and disease-free survival in early breast cancer patients receiving tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

Limited effects of frequent CYP2D6*36-*10 tandem duplication allele on in vivo dextromethorphan metabolism in a Japanese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

Multidrug resistance through the spectacle of P-glycoprotein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

Endoxifen, the active metabolite of tamoxifen, is a substrate of the efflux transporter P-glycoprotein (multidrug resistance 1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

Induction of multidrug resistance associated protein 2 in tamoxifen-resistant breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

A genome-wide association study identifies locus at 10q22 associated with clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients in Japanese

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

Biological determinants of endocrine resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

Biological mechanisms and clinical implications of endocrine resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

Repeated observation of breast tumor subtypes in independent gene expression data sets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

HOXB13-to-IL17BR expression ratio is related with tumor aggressiveness and response to tamoxifen of recurrent breast cancer: a retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

Cytochrome P450 2D6 and homeobox 13/interleukin-17B receptor: combining inherited and tumor gene markers for prediction of tamoxifen resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

Lack of any association between functionally significant CYP2D6 polymorphisms and clinical outcomes in early breast cancer patients receiving adjuvant tamoxifen treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

7 January 2021

Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

7 January 2021

Sulfation of raloxifene and 4-hydroxytamoxifen by human cytosolic sulfotransferases

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

7 January 2021

Evidence for a new variant CYP2D6 allele CYP2D6J in a Japanese population associated with lower in vivo rates of sparteine metabolism.

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

7 January 2021

Analysis of the CYP2D6 gene in relation to dextromethorphan O-demethylation capacity in a Japanese population

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

7 January 2021

Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: polymorphism in RFLP and DNA sequence of CYP2D6

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

7 January 2021

A new CYP2D6 allele with a nine base insertion in exon 9 in a Japanese population associated with poor metabolizer phenotype

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

7 January 2021

A new variant CYP2D6 allele (CYP2D6*21) with a single base insertion in exon 5 in a Japanese population associated with a poor metabolizer phenotype

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

7 January 2021

Two novel haplotypes of CYP2D6 gene in a Japanese population

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

7 January 2021

Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

7 January 2021

Genetic polymorphisms of CYP2D6 increase the risk for recurrence of breast cancer in patients receiving tamoxifen as an adjuvant therapy

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

7 January 2021

Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

7 January 2021

Increasing tamoxifen dose in breast cancer patients based on CYP2D6 genotypes and endoxifen levels: effect on active metabolite isomers and the antiestrogenic activity score

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

7 January 2021

Dose-adjustment study of tamoxifen based on CYP2D6 genotypes in Japanese breast cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

7 January 2021

CYP2D6 genotyping for functional-gene dosage analysis by allele copy number detection

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

7 January 2021

Multiplex PCR-based real-time invader assay (mPCR-RETINA): a novel SNP-based method for detecting allelic asymmetries within copy number variation regions

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

7 January 2021

P-glycoprotein (ABCB1) transports the primary active tamoxifen metabolites endoxifen and 4-hydroxytamoxifen and restricts their brain penetration

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

7 January 2021

Whole-genome analysis informs breast cancer response to aromatase inhibition

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.39

7 January 2021

Identifiers

DOI

10.1038/JHG.2013.39

1 reference

Dimensions Publication ID

28 August 2017

1043934262

0 references

1 reference